The US Food and Drug Administration (FDA) has issued warning letters to CVS, Walgreens, and other companies for manufacturing and marketing unapproved eye products that could pose risks to users. The products, illegally marketed to treat conditions such as conjunctivitis, glaucoma, and cataracts, were found to have sterility issues and some contained silver, which can cause permanent discoloration of the skin or eye. The FDA is concerned about the potential harm these unapproved drugs may cause, as they bypass the body's natural defenses. The companies have 15 days to respond and correct violations, or face legal action. CVS and Walgreens have already pulled the products from their shelves.
The U.S. Food and Drug Administration (FDA) has issued warnings to eight companies, including CVS Health Corp and Walgreens Boots Alliance, for manufacturing or marketing unapproved eye products. These products are illegally marketed to treat conditions such as conjunctivitis, cataract, and glaucoma, posing an increased risk to users. Some of the products contain silver, which can cause permanent discoloration of the skin and eye tissues. CVS has already halted the sale of its "Pink Eye Relief Eye Drops" and is offering full refunds to customers. The FDA has given the companies 15 days to respond and correct the violations, warning that failure to do so may result in legal action.
The FDA has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products, including eye products labeled to contain silver. These products are illegally marketed to treat conditions such as conjunctivitis, cataracts, and glaucoma. The FDA is concerned about the potential harm these unapproved drugs may cause, as they bypass the body's natural defenses and may lead to permanent discoloration of the skin and eye. Consumers are advised to consult their healthcare professionals if they are using any of the products mentioned in the warning letters. The FDA has requested the companies to respond within 15 days and failure to comply may result in legal action.
